The Insightful Corner Hub: Why Are Suicide Rates Rising Among USA Pharmacists? Insights from a 15-Year Study (2003–2018)

 

Meta Description:

Explore the reasons behind elevated suicide rates among pharmacists between 2003 and 2018. Learn about occupational stress, mental health challenges, and prevention strategies based on recent research.

Introduction

Suicide is a critical public health concern that affects people across all professions. Recent research reveals an alarming trend: pharmacists are at a significantly higher risk of suicide than the general population. This article explores key findings from a comprehensive 15-year study on pharmacist suicides, examines underlying causes, and discusses vital prevention strategies.

Elevated Suicide Rates Among Pharmacists: What the Research Shows

A longitudinal analysis by Lee et al. covering 2003 to 2018 found that pharmacists experienced suicide rates approximately 1.5 times higher than the general public, with rates reaching about 19–20 per 100,000 pharmacists compared to around 12 per 100,000 among others.

Among pharmacist suicides, 75% were male, 85% were White, and the average age was 53.5 years indicating potential career stage vulnerabilities.

Read also: 

• Understanding the Silent Battle: Exploring the Impact of Depression among Pharmacists
• The Global Epidemiology of Depression Among Pharmacists: Understanding the Scope of the Issue
• The Silent Battle: Understanding Health Professionals' Depression

What We Know Today

A 15-year analysis of U.S. mortality data (2003–2018) published in the Journal of the American Pharmacists Association quantified suicide among pharmacists and compared characteristics to suicides among nonpharmacists. The study used the Centers for Disease Control and Prevention’s National Violent Death Reporting System (NVDRS) and identified 316 suicide deaths coded as pharmacists in that period, compared with more than 213,000 suicides among nonpharmacists in the same dataset. Age-adjusted suicide rates for pharmacists were reported in the study as roughly 20 per 100,000 higher than the general-population estimate for the same time window (approximately 12 per 100,000 by the study authors’ comparison). The most commonly documented means among pharmacist suicides was firearm use; when available, contributing circumstances frequently included job-related problems, current treatment for mental illness, and the presence of a suicide note (PMC+1).

It is important to emphasize one central point: the 2003–2018 analysis is descriptive. It reports rates, methods, and coded circumstances associated with deaths but does not establish causal mechanisms explaining any increases or differences. In other words, the study documents what the NVDRS data show (rates, demographics, and coded circumstances) rather than why individual pharmacists died by suicide. Any discussion that leaps from these descriptive findings to definitive causes would be speculative and should be avoided (PMC).

How this fits into the broader U.S. suicide landscape

National surveillance shows fluctuations in U.S. suicide rates over recent decades. The CDC notes that overall U.S. suicide rates rose substantially from 2000 to around 2018 (a ~30–37% increase reported in multiple CDC summaries), with a modest decline in 2019–2020 and then increases again by 2022 in some provisional data patterns that differ across age groups, sexes, and regions. Those national trends provide necessary context for understanding occupational subgroups but do not by themselves explain occupational differences (cdc.gov+1).

What the NVDRS study actually found (key, evidence-based points)

• Higher observed rate among pharmacists (2003–2018): The study reported an age-adjusted rate around 20 per 100,000 for pharmacists versus ~12 per 100,000 in the general population for the same period (as used by the study authors for comparison) (PMC+1).
• Means of death: Firearms were the most common method documented in pharmacist suicides in the sample (PMC).
• Coded contributing circumstances: The NVDRS incident and investigative narratives often included job problems, ongoing treatment for mental illness, and suicide notes as frequently appearing circumstances among the pharmacist cases. These are associations observed in records, not proven causal factors (PMC).
• Data coverage and limits: The analysis used NVDRS data from states and jurisdictions participating during the study window; not every U.S. state contributed data the entire time, and occupation coding depends on how decedents’ jobs were recorded, which introduces potential misclassification and incompleteness. The authors explicitly note these and other limitations (PMC).

Limitations to keep front-and-center (why cautious language matters)

When discussing occupation-specific suicide rates, we must account for methodological constraints: NVDRS depends on death investigation records and how occupation is recorded; some deaths may lack full circumstance coding; and workforce denominators used to compute occupation-specific rates can be uncertain. These data limitations mean we should avoid asserting definitive causal explanations from the 2003–2018 analysis alone. Put simply: the study identifies troubling patterns that justify further, targeted investigation, not proof of specific causal pathways (PMC)

More recent context and ongoing work

Researchers and professional groups have continued work after 2018 to understand healthcare worker mental health and occupational risk. Reviews and surveillance analyses published since 2019 examine broader healthcare worker trends, pandemic impacts, and occupational mental health supports. Programs to train pharmacists as gatekeepers (for example, Pharm-SAVES and other training models) and to integrate pharmacists into community suicide prevention strategies have been developed and evaluated, though direct evidence linking those trainings to reductions in pharmacist suicides remains limited and requires rigorous evaluation (PMC+1)

What the evidence supports in terms of action

Given the descriptive findings and the broader body of work on clinician mental health, a cautious, evidence-based approach is to prioritize prevention strategies that are supported or plausible and to evaluate them carefully. These include:

• Improving access to confidential mental health care for pharmacists and reducing professional penalties or barriers that deter help-seeking.
• Gatekeeper training so pharmacists can better identify and refer people at risk, while also receiving training in how to cope with patient-facing suicidal crises and their emotional impact (PMC+1).
• Workplace supports and post-vention (structured support after a traumatic event or a colleague’s death) to mitigate distress among staff who are exposed to patient suicides or workplace crises (fip.org).
• Lethal-means safety practices in community pharmacy (for example, limiting large quantities of potentially lethal medications in specific contexts) as part of broader suicide-prevention toolkits implemented thoughtfully and in coordination with clinical partners (ScienceDirect)

Bottom line

The 2003–2018 NVDRS analysis shows a measurable and concerning pattern: pharmacists in that dataset had higher observed suicide rates and certain recurring circumstances (e.g., job problems, current mental illness treatment, presence of a suicide note) compared with nonpharmacists. Those findings are descriptive and do not explain causal mechanisms. To responsibly address the problem, stakeholders should combine improved surveillance (including post-2018 and pandemic-era data), qualitative research to understand context, and rigorous evaluation of prevention strategies—while avoiding speculative explanations that exceed what the data support. 

---

Call to Action: Please share the article to raise awareness or contact mental health support resources.